Since thoracic MR imaging was first used in a clinical setting, it has been suggested that MR imaging has limited clinical utility for thoracic diseases, especially lung diseases, in comparison with x-ray CT and positron emission tomography (PET)/CT. However, in many countries and states and for specific indications, MR imaging has recently become practicable. In addition, recently developed pulmonary MR imaging with ultra-short TE (UTE) and zero TE (ZTE) has enhanced the utility of MR imaging for thoracic diseases in routine clinical practice. Furthermore, MR imaging has been introduced as being capable of assessing pulmonary function. It should be borne in mind, however, that these applications have so far been academically and clinically used only for healthy volunteers, but not for patients with various pulmonary diseases in Japan or other countries. In 2020, the Fleischner Society published a new report, which provides consensus expert opinions regarding appropriate clinical indications of pulmonary MR imaging for not only oncologic but also pulmonary diseases. This review article presents a brief history of MR imaging for thoracic diseases regarding its technical aspects and major clinical indications in Japan 1) in terms of what is currently available, 2) promising but requiring further validation or evaluation, and 3) developments warranting research investigations in preclinical or patient studies. State-of-the-art MR imaging can non-invasively visualize lung structural and functional abnormalities without ionizing radiation and thus provide an alternative to CT. MR imaging is considered as a tool for providing unique information. Moreover, prospective, randomized, and multi-center trials should be conducted to directly compare MR imaging with conventional methods to determine whether the former has equal or superior clinical relevance. The results of these trials together with continued improvements are expected to update or modify recommendations for the use of MRI in near future.

To demonstrate the utility of compressed sensing with parallel imaging (Compressed SPEEDER) and AiCE compared with that of conventional parallel imaging (SPEEDER) for shortening examination time and improving image quality of women's pelvic MRI. Method: Thirty consecutive patients with women's pelvic diseases (mean age 50 years) underwent T2-weighted imaging using Compressed SPEEDER as well as conventional SPEEDER reconstructed with and without AiCE. The examination times were recorded, and signal-to-noise ratio (SNR) was calculated for every patient. Moreover, overall image quality was assessed using a 5-point scoring system, and final scores for all patients were determined by consensus of two readers. Mean examination time, SNR and overall image quality were compared among the four data sets by Wilcoxon signed-rank test. Results: Examination times for Compressed SPEEDER with and without AiCE were significantly shorter than those for conventional SPEEDER with and without AiCE (with AiCE: p < 0.0001, without AiCE: p < 0.0001). SNR of Compressed SPEEDER and of SPEEDER with AiCE was significantly superior to that of Compressed SPEEDER without AiCE (vs. Compressed SPEEDER, p = 0.01; vs. SPEEDER, p = 0.009). Overall image quality of Compressed SPEEDER with AiCE and of SPEEDER with and without AiCE was significantly higher than that of Compressed SPEEDER without AiCE (vs. Compressed SPEEDER with AiCE, p < 0.0001; vs. SPEEDER with AiCE, p < 0.0001; SPEEDER without AiCE, p = 0.0003). Conclusion: Image quality and shorten examination time for T2-weighted imaging in women's pelvic MRI can be significantly improved by using Compressed SPEEDER with AiCE in comparison with conventional SPEEDER, although other sequences were not tested.

No abstract

This study sought to determine the diagnostic utility of perfusion parameters derived from dynamic contrast-enhanced (DCE) perfusion MRI with a short acquisition time (approximately 3.5 min) in patients with glioma, brain metastasis, and primary CNS lymphoma (PCNSL).Twenty-six patients with 29 lesions (4 low-grade glioma, 13 high-grade glioma, 7 metastasis, and 5 PCNSL) underwent DCE-MRI in a 3 T scanner. A ROI was placed on the hotspot of each tumor in maps for volume transfer contrast Ktrans, extravascular extracellular volume Ve, and fractional plasma volume Vp. We analyzed differences in parameters between tumors using the Mann–Whitney U test. We calculated sensitivity and specificity using receiver operating characteristics analysis.Mean Ktrans values of LGG, HGG, metastasis and PCNSL were 0.034, 0.31, 0.38, 0.44, respectively. Mean Ve values of each tumors was 0.036, 0.57, 0.47, 0.96, and mean Vp value of each tumors was 0.070, 0.086, 0.26, 0.17, respectively. Compared with other tumor types, low-grade glioma showed lower Ktrans (P < 0.01, sensitivity = 88%, specificity = 100%) and lower Ve (P < 0.01, sensitivity = 96%, specificity = 100%). PCNSL showed higher Ve (P < 0.01, sensitivity = 100%, specificity = 88%), but the other perfusion parameters overlapped with those of different histology.Kinetic parameters derived from DCE-MRI with short acquisition time provide useful information for the differential diagnosis of brain tumors.